- Home
- RFAM vs PLYX Comparison
RFAM vs PLYX Comparison
Compare RFAM & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RFAM | PLYX |
|---|---|---|
| Founded | 2025 | 2014 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.5M | 112.7M |
| IPO Year | 2025 | 2025 |
Fundamental Metrics
Financial Performance| Metric | RFAM | PLYX |
|---|---|---|
| Price | $10.00 | $1.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 12.5K | ★ 24.7K |
| Earning Date | N/A | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.53 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.77 | $1.69 |
| 52 Week High | $10.02 | $10.93 |
Technical Indicators
Market Signals| Indicator | RFAM | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 58.08 | 44.72 |
| Support Level | $9.77 | N/A |
| Resistance Level | $10.02 | $2.18 |
| Average True Range (ATR) | 0.01 | 0.11 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 66.67 | 46.66 |
Price Performance
Historical ComparisonAbout RFAM RF Acquisition Corp III Ordinary Shares
RF Acquisition Corp III is a blank check company incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination.
About PLYX Polaryx Therapeutics Inc. Common Stock
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.